<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Monoclonal Antibodies

Name: Monoclonal Antibodies
Creator: Geskin, Larisa J.
Keywords: Brentuximab Vedotin, 0301 basic medicine, Clinical Trials as Topic, 0303 health sciences, Antibody conjugates, Immunoconjugates, Skin Neoplasms, Recombinant Fusion Proteins, Antibodies, Monoclonal, Antineoplastic Agents

descriptionPublicationkeyboard_double_arrow_right Article 01 Oct 2015 English Publisher:Elsevier BVJournal:Dermatologic Clinics, volume 33, pages 777-786 (issn: 0733-8635,

Authors: Geskin, Larisa J.;

doi: 10.1016/j.det.2015.05.015

pmid: 26433849

Monoclonal Antibodies

- Summary
- Subjects
- Metrics

Abstract

Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas. mAb-based therapy for cutaneous T-cell lymphoma has demonstrated high response rates and a favorable toxicity profile in clinical trials. Several antibodies and antibody-based conjugates are approved for use in clinical practice, and many more are in ongoing and planned clinical trials. In addition, these safe and effective drugs can be used as pillars for sequential therapies in a rational stepwise manner.

Related Organizations

King’s University
United States

Keywords

Brentuximab Vedotin, Clinical Trials as Topic, Antibody conjugates, Immunoconjugates, Skin Neoplasms, Recombinant Fusion Proteins, Antibodies, Monoclonal, Antineoplastic Agents, Dermatology, Antibodies, Monoclonal, Humanized, Lymphoma, T-Cell, Cutaneous, Clinical trials, Cutaneous lymphoma, Antineoplastic Combined Chemotherapy Protocols, Humans, Interleukin-2, Diphtheria Toxin, Antibody therapy, Molecular Targeted Therapy, Alemtuzumab

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	19
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%